LUND, Sweden, Mar 23, 2017 /PRNewswire/ --
NeuroVive Pharmaceutical AB (Nasdaq Stockholm: NVP,OTCQX: NEVPF), the mitochondrial medicine company, today announced that the English version of the Annual report for 2016 is now available on the company's website www.neurovive.com.
NeuroVive Pharmaceutical AB is a leader in mitochondrial medicine. The company is committed to the discovery and development of medicines that preserve mitochondrial integrity and function in areas of unmet medical need. The company's strategy is to take drugs for rare diseases through clinical development and into the market. The strategy for projects within larger indications outside the core focus area is out-licensing in the preclinical phase. NeuroVive enhances the value of its projects in an organization that includes strong international partnerships and a network of mitochondrial research institutions, as well as expertise with capacities within drug development and production.
NeuroVive has a project in early clinical phase II development for the prevention of moderate to severe traumatic brain injury (NeuroSTAT®). NeuroSTAT has orphan drug designation in Europe and in the US. The R&D portfolio consists of several late stage research programs in areas ranging from genetic mitochondrial disorders to cancer and metabolic diseases such as NASH.
NeuroVive is listed on Nasdaq Stockholm, Sweden (ticker: NVP). The share is also traded on the OTCQX Best Market in the US (OTC: NEVPF).
For investor relations and media questions, please contact:
Tel: +46-(0)46-275-62-21 or [email protected]
NeuroVive Pharmaceutical AB (publ)
SE-223 81 Lund, Sweden
Tel: +46-(0)46-275-62-20 (switchboard)
This information is information that NeuroVive Pharmaceutical AB (publ) is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact person set out above, at 08:35 a.m. CET on March 23, 2017.
This information was brought to you by Cision http://news.cision.com
The following files are available for download:
NeuroVive Pharmaceutical AB publishes 2016 Annual report
SOURCE NeuroVive Pharmaceutical